Strides Pharma Science Ltd

Business Update

Strides Pharma Science Business Update

Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.

Earnings Call

Strides Pharma Science Earnings Call Transcript: Key Takeaways

Strides Pharma Science reported Q1 FY27 results with 13% YoY revenue growth and EBITDA margins maintained at 18.2%. Strategy focuses on Ex-US growth and US portfolio diversification.

Call

Guides 32% growth

Earnings Call

Strides Pharma Science Investor Presentation: Key Takeaways

Strides Q1FY27 revenue grew 13% YoY to ₹12,654m, led by a 17% surge in Ex-US markets. Operational PAT stood at ₹1,231m.

Financial ResultsAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Strides Pharma Science Q1 FY27 Results: Net Profit ₹165.5 Cr, Up 56.7% YoY

Strides Pharma Science Ltd reported revenue from operations of ₹1,265 Cr (+13.0% YoY) and net profit of ₹165.5 Cr (+56.7% YoY) for Q1 FY27.

Key figure

Net profit ₹165.5 Cr · +56.7% YoY